Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SinoMab BioScience Limited
中國抗體製藥有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 3681)

VOLUNTARY ANNOUNCEMENT

IND APPLICATION FOR SM03 (SUCIRASLIMAB) FOR THE TREATMENT OF ALZHEIMER'S DISEASE ACCEPTED BY NMPA CDE

This announcement is made by SinoMab BioScience Limited (中國抗體製藥有限公司) (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest research and development progress of the Company's flagship product, SM03 (Suciraslimab).

The board of directors (the "**Board**") of the Company is pleased to announce that on 14 November 2023, an Investigational New Drug application ("**IND**"), for Mild Cognitive Impairment ("**MCI**") or Mild Dementia due to Alzheimer's Disease ("**AD**") for Suciraslimab has been filed with and accepted by the Center for Drug Evaluation (the "**CDE**") of the National Medical Products Administration of China (the "**NMPA**"). The Company plans to initiate the Phase I clinical study in China upon approval of the present IND. The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of early phase symptomatic AD, including MCI or Mild Dementia due to AD.

Suciraslimab is the Company's self-developed product and is a first-in-class anti-CD22 monoclonal antibody for the treatment of rheumatoid arthritis ("**RA**"), and potentially other diseases such as systemic lupus erythematosus (SLE), non-Hodgkin's lymphoma (NHL), Sjogren's syndrome (SS) as well as Alzheimer's Disease (AD). It adopts a novel mechanism of action, which differentiates itself from the current treatments available in the market. Currently, there are relatively high worsening rates existing between mild cognitive impairment and mild dementia, as well as mild dementia and moderate to severe dementia due to Alzheimer's Disease, thus, the key therapeutic strategy for the disease is to delay the disease progression, and prevent the situation of mild dementia from turning into moderate to severe dementia. Suciraslimab is also developed in accordance with this strategy in Alzheimer's Disease. Suciraslimab, upon binding to CD22, promotes the clearance of β-amyloid and simultaneously suppresses neuroinflammation, offering a therapeutic

advantage over other approved products which clear β-amyloid at the expense of neuroinflammation. With this unique mechanism of action, Suciraslimab could potentially reduce the risk of serious adverse reactions commonly associated with anti-β-amyloid treatments such as amyloid-related imaging abnormalities-Edema (ARIA-E) and Amyloid-related imaging abnormalities-hemorrhage (ARIA-H).

A biologics license application for Suciraslimab in the treatment of RA was accepted by the NMPA in September 2023 and is currently under technical review. A Phase III extension study on RA is also ongoing in China.

Cautionary Statement required by Rule 18A.05 of the Rules of Governing the Listing of Securities on the Stock Exchange: The Company cannot guarantee that it will be able to ultimately develop and market Suciraslimab successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 15 November 2023

As at the date of this announcement, the executive director is Dr. Shui On LEUNG, the non-executive directors are Dr. Haigang CHEN, Mr. Xun DONG, Dr. Wenyi LIU, Mr. Lei SHI and Dr. Jianmin ZHANG, and the independent non-executive directors are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.